travere therapeutics inc - TVTX
TVTX
Close Chg Chg %
46.18 -0.37 -0.80%
Closed Market
45.81
-0.37 (0.80%)
Volume: 2.91M
Last Updated:
Jun 5, 2026, 4:00 PM EDT
Company Overview: travere therapeutics inc - TVTX
TVTX Key Data
| Open $46.50 | Day Range 45.30 - 47.77 |
| 52 Week Range 13.88 - 48.60 | Market Cap $4.29B |
| Shares Outstanding 92.99M | Public Float 90.35M |
| Beta 1.13 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.50 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.40M |
TVTX Performance
| 1 Week | -2.90% | ||
| 1 Month | 7.54% | ||
| 3 Months | 68.17% | ||
| 1 Year | 199.02% | ||
| 5 Years | 224.66% |
TVTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
15
Full Ratings ➔
About travere therapeutics inc - TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
TVTX At a Glance
Travere Therapeutics, Inc.
3611 Valley Centre Drive
San Diego, California 92130
| Phone | 1-888-969-7879 | Revenue | 490.73M | |
| Industry | Pharmaceuticals: Major | Net Income | -50,261,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 110.455% | |
| Fiscal Year-end | 12 / 2026 | Employees | 497 | |
| View SEC Filings |
TVTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.946 |
| Price to Book Ratio | 30.255 |
| Price to Cash Flow Ratio | 90.22 |
| Enterprise Value to EBITDA | -1,640.904 |
| Enterprise Value to Sales | 6.958 |
| Total Debt to Enterprise Value | 0.096 |
TVTX Efficiency
| Revenue/Employee | 987,380.282 |
| Income Per Employee | -101,128.773 |
| Receivables Turnover | 6.026 |
| Total Asset Turnover | 0.818 |
TVTX Liquidity
| Current Ratio | 2.736 |
| Quick Ratio | 2.70 |
| Cash Ratio | 2.019 |
TVTX Profitability
| Gross Margin | 85.515 |
| Operating Margin | -12.802 |
| Pretax Margin | -10.041 |
| Net Margin | -10.242 |
| Return on Assets | -8.382 |
| Return on Equity | -57.803 |
| Return on Total Capital | -11.331 |
| Return on Invested Capital | -12.195 |
TVTX Capital Structure
| Total Debt to Total Equity | 286.283 |
| Total Debt to Total Capital | 74.112 |
| Total Debt to Total Assets | 54.319 |
| Long-Term Debt to Equity | 281.167 |
| Long-Term Debt to Total Capital | 72.788 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Travere Therapeutics Inc - TVTX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 212.02M | 145.24M | 233.18M | 490.73M | |
Sales Growth
| -6.80% | -31.50% | +60.55% | +110.45% | |
Cost of Goods Sold (COGS) incl D&A
| 40.67M | 49.98M | 51.30M | 71.08M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 33.08M | 38.53M | 43.55M | 60.74M | |
Depreciation
| 2.12M | 2.25M | 1.82M | 1.53M | |
Amortization of Intangibles
| 30.96M | 36.28M | 41.74M | 59.21M | |
COGS Growth
| +21.77% | +22.89% | +2.64% | +38.56% | |
Gross Income
| 171.35M | 95.26M | 181.88M | 419.65M | |
Gross Income Growth
| -11.72% | -44.41% | +90.93% | +130.73% | |
Gross Profit Margin
| +80.82% | +65.59% | +78.00% | +85.51% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 422.91M | 472.00M | 438.06M | 482.47M | |
Research & Development
| 229.52M | 237.73M | 217.50M | 206.01M | |
Other SG&A
| 193.39M | 234.27M | 220.56M | 276.46M | |
SGA Growth
| +26.77% | +11.61% | -7.19% | +10.14% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 22.58M | 11.39M | 67.64M | |
EBIT after Unusual Expense
| (274.14M) | (388.14M) | (323.83M) | (62.82M) | |
Non Operating Income/Expense
| 7.25M | 23.36M | 14.50M | 24.30M | |
Non-Operating Interest Income
| 6.28M | 21.77M | 17.82M | 12.72M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 11.28M | 11.33M | 11.18M | 10.75M | |
Interest Expense Growth
| -44.02% | +0.52% | -1.34% | -3.88% | |
Gross Interest Expense
| 11.28M | 11.33M | 11.18M | 10.75M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (278.17M) | (376.11M) | (320.51M) | (49.27M) | |
Pretax Income Growth
| -54.81% | -35.21% | +14.78% | +84.63% | |
Pretax Margin
| -131.20% | -258.96% | -137.45% | -10.04% | |
Income Tax
| 313.00K | 223.00K | 120.00K | 988.00K | |
Income Tax - Current - Domestic
| 314.00K | 223.00K | 120.00K | 988.00K | |
Income Tax - Current - Foreign
| - | - | - | (1.00K) | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (278.48M) | (376.33M) | (320.63M) | (50.26M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (278.48M) | (376.33M) | (320.63M) | (50.26M) | |
Net Income Growth
| -54.63% | -35.14% | +14.80% | +84.32% | |
Net Margin Growth
| -131.35% | -259.11% | -137.51% | -10.24% | |
Extraordinaries & Discontinued Operations
| - | - | 38.93M | (915.00K) | - |
Discontinued Operations
| - | - | 38.93M | (915.00K) | - |
Net Income After Extraordinaries
| (278.48M) | (337.40M) | (321.55M) | (50.26M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (278.48M) | (337.40M) | (321.55M) | (50.26M) | |
EPS (Basic)
| -4.3678 | -4.5431 | -4.0759 | -0.5634 | |
EPS (Basic) Growth
| -45.11% | -4.01% | +10.28% | +86.18% | |
Basic Shares Outstanding
| 63.76M | 74.27M | 78.89M | 89.21M | |
EPS (Diluted)
| -4.3678 | -4.5431 | -4.0759 | -0.5634 | |
EPS (Diluted) Growth
| -45.11% | -4.01% | +10.28% | +86.18% | |
Diluted Shares Outstanding
| 63.76M | 74.27M | 78.89M | 89.21M | |
EBITDA
| (218.48M) | (338.21M) | (212.63M) | (2.08M) | |
EBITDA Growth
| -93.54% | -54.80% | +37.13% | +99.02% | |
EBITDA Margin
| -103.05% | -232.87% | -91.19% | -0.42% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 54.857 | |
| Number of Ratings | 15 | Current Quarters Estimate | -0.052 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 0.232 | |
| Last Quarter’s Earnings | -0.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.29 | Next Fiscal Year Estimate | 2.52 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 12 | 12 |
| Mean Estimate | -0.05 | -0.06 | 0.23 | 2.52 |
| High Estimates | 0.42 | 0.27 | 2.53 | 5.95 |
| Low Estimate | -0.37 | -0.80 | -1.20 | -0.17 |
| Coefficient of Variance | -443.27 | -545.43 | 435.60 | 79.42 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 14 | 13 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Travere Therapeutics Inc - TVTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Travere Therapeutics Inc - TVTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 17, 2026 | Roy D. Baynes Director | 63,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.38 per share | 1,357,630.00 |
| Apr 17, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | 57,830 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.93 per share | 516,421.90 |
| Apr 17, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | 51,580 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.4 per share | 1,155,392.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 6,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 4,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 4,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 37,500 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $42.12 per share | 1,579,500.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 44,250 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.07 per share | 1,817,347.50 |
| Apr 17, 2026 | Roy D. Baynes Director | 70,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.11 per share | 1,201,977.50 |
| Apr 17, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | 5,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 59,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.27 per share | 1,077,930.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 54,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.43 per share | 840,935.00 |
| Apr 17, 2026 | Roy D. Baynes Director | 45,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.94 per share | 816,270.00 |
| Apr 17, 2026 | Gary A. Lyons Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2026 | Gary A. Lyons Director | 57,500 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.07 per share | 2,361,525.00 |
| Apr 17, 2026 | Gary A. Lyons Director | 65,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.33 per share | 1,069,615.00 |
| Apr 17, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | 64,330 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $20.46 per share | 1,316,191.80 |
| Apr 17, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | 42,353 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.07 per share | 1,739,437.71 |